Get started
Author

Arangassery Rosemary Bastian

Observed names: A R Bastian, A.R. Bastian, Arangaserry R. Bastian, Arangaserry Rosemary Bastian, Arangassery R Bastian, Arangassery R. Bastian, Arangassery Rosemary Bastian, Bastian, Arangassery Rosemary
Observed institutions: Northwestern University, Janssen (Belgium), Duke University, University of Dhaka, University of Rochester Medicine, Janssen (Netherlands), Johnson & Johnson (Netherlands), Chemistry of Life Processes Institute, University of Rochester, Drexel University
OpenAlex ID: A5000625709
Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults
2023 · Ann R. Falsey, Kristi Williams, et al. · New England Journal of Medicine · 153
PDF
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years
2020 · Kristi Williams, Arangassery Rosemary Bastian, et al. · The Journal of Infectious Diseases · 106
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
2021 · Jerald Sadoff, Els De Paepe, et al. · The Journal of Infectious Diseases · 88
PDF
Solid‐State Nanopore Detection of Protein Complexes: Applications in Healthcare and Protein Kinetics
2012 · Kevin J. Freedman, Arangassery R. Bastian, et al. · Small · 72
Antibody effector functions are associated with protection from respiratory syncytial virus
2022 · Yannic C. Bartsch, Deniz Cizmeci, et al. · Cell · 62
Mechanism of Multivalent Nanoparticle Encounter with HIV-1 for Potency Enhancement of Peptide Triazole Virus Inactivation
2014 · Arangassery Rosemary Bastian, Aakansha Nangarlia, et al. · Journal of Biological Chemistry · 57
PDF
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults
2020 · Jerald Sadoff, Els De Paepe, et al. · The Journal of Infectious Diseases · 52
PDF
Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16
2016 · B.M. Gunn, J.R. Schneider, et al. · Mucosal Immunology · 49
PDF
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
2022 · Arabella S V Stuart, Miia Virta, et al. · The Journal of Infectious Diseases · 41
PDF
Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions
2013 · Arangassery Rosemary Bastian, Mark Contarino, et al. · Retrovirology · 41
PDF
Cell‐Free HIV‐1 Virucidal Action by Modified Peptide Triazole Inhibitors of Env gp120
2011 · Arangassery R. Bastian, Kantharaju, et al. · ChemMedChem · 41
Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study
2024 · Ann R Falsey, Tessa Hosman, et al. · The Lancet Infectious Diseases · 28
Chimeric Cyanovirin-MPER Recombinantly Engineered Proteins Cause Cell-Free Virolysis of HIV-1
2013 · Mark Contarino, Arangassery R. Bastian, et al. · Antimicrobial Agents and Chemotherapy · 24
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF–Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study
2023 · Christy A Comeaux, Stephan Bart, et al. · The Journal of Infectious Diseases · 21
PDF
Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model
2023 · T Van Effelterre, N Hens, et al. · Clinical Infectious Diseases · 21
PDF
Long-term direct visualization of passively transferred fluorophore-conjugated antibodies
2017 · Jeffrey R. Schneider, Ann M. Carias, et al. · Journal of Immunological Methods · 21
RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
2023 · Freek Cox, Eirikur Saeland, et al. · Vaccines · 20
PDF
Disulfide Sensitivity in the Env Protein Underlies Lytic Inactivation of HIV-1 by Peptide Triazole Thiols
2015 · Lauren D. Bailey, Ramalingam Venkat Kalyana Sundaram, et al. · ACS Chemical Biology · 18
LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
2021 · Ann R Falsey, Kristi Williams, et al. · Open Forum Infectious Diseases · 14
T cells, more than antibodies, may prevent symptoms developing from respiratory syncytial virus infections in older adults
2023 · Bruno Salaun, Jonathan De Smedt, et al. · Frontiers in Immunology · 13
PDF
Impact of HIV-1 Membrane Cholesterol on Cell-Independent Lytic Inactivation and Cellular Infectivity
2015 · Ramalingam Venkat Kalyana Sundaram, Huiyuan Li, et al. · Biochemistry · 11
Covalent Conjugation of a Peptide Triazole to HIV-1 gp120 Enables Intramolecular Binding Site Occupancy
2014 · Ali Emileh, Caitlin Duffy, et al. · Biochemistry · 11
PDF
902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
2019 · John DeVincenzo, Efi Gymnopoulou, et al. · Open Forum Infectious Diseases · 10
A Randomized, Double‐Blind, Placebo‐Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF‐Based Regimen in Japanese Adults Aged 60 Years and Older
2024 · Takashi Eto, Yusuke Okubo, et al. · Influenza and Other Respiratory Viruses · 9
PDF
A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12–24 Months
2024 · Joanne M Langley, Terry M Nolan, et al. · Open Forum Infectious Diseases · 8
PDF
Works count: 49
Citation count: 1,046
H-index: 18
I10-index: 23
Year
Topic
Type